Xerostomia Therapeutics Market

Xerostomia Therapeutics Market

Segments - by Types (Over the counter and Prescription), Products (Salivary Stimulants, Dentifrices, and Salivary Substitutes), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2215
  • Author: Growth Market Reports
  • Rating: 4.7
  • Total Reviews: 56
  • No. Of Pages: 178
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global xerostomia therapeutics market size is anticipated to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing demand for chemotherapy and radiotherapy in cancer treatment market.

Xerostomia Therapeutics Market summary

Xerostomia is a dry mouth condition and is commonly caused due to absent of salivary flow producing mucosal dryness. The rise in chemotherapy and radiation therapy is expected to lead to an increased incidences of xerostomia. Adoption of radiation and chemotherapy to undergo for the cancer treatment is likely to damage the salivary gland and develop effects such as dryness in mouth. Every year, about 640,000 cancer patients receive chemotherapy treatment that are mainly prescribed by medical practitioners, according to the Centers for Disease Control & Prevention (CDC). It was estimated that over 3.4 million women suffered from breast cancer in the U.S. in January 1, 2016, as per a report published by American Cancer Society. Around 48% of the women with stage IV breast cancer are most likely to receive chemotherapy or radiation.

Products including saliva substitute gels, lozenges, toothpastes, oral-adhering discs, sugar-free chewing gums patches, mouthwashes & oral rinses, and melts are some of the key medications available in the market. However, the prices of these products range from USD 10 to 90 and yet there are favorable remuneration policies of these products across several countries. For instance, funds are provided to patients with radiation-induced xerostomia undergoing treatment with drug under the Exceptional Access Program by Ontario Ministry of Health and Long-Term Care.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing acceptance of radiotherapy and chemotherapy in cancer treatment with increasing use of prescribed medications are some of the key factors expected to fuel the market growth.
  • Easy available and cost-effective medications are some of the key drivers of the market. 
  • Favorable government policies such as easy accessibility to reimbursement policies and other favorable policies of the patients are expected to accelerate the market expansion.
  • Certain advantages such as safety & efficacy, availability of limited branded drugs, wide variety & availability, and low pricing of products are other key drivers of the market growth.

Scope of the Report                          

The report on the global xerostomia therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Xerostomia Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (Over the counter and Prescription) and Products (Salivary Stimulants, Dentifrices, and Salivary Substitutes)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Church & Dwight Co., Inc.; GlaxoSmithKline Plc; Hikma Pharmaceuticals Plc; Pendopharm, Inc; Sun Pharmaceuticals Industries Ltd.; Pfizer, Inc.; Parnell Pharmaceuticals, Inc.; Lupin Pharmaceuticals, Inc.; Colgate-Palmolive Company; OraCoat; and Acacia Pharma Ltd.

Market Segment Insights

Over the counter segment is expected to grow at a rapid pace

Based on types, the global xerostomia therapeutics market is divided into over the counter (OTC) and prescription. The OTC segment is expected to grow at a rapid pace in the coming years owing to safety & efficacy, wide variety & availability, and low pricing of products of OTC drugs. However, the prescription segment is anticipated to accounts for a key share of the market during the forecast period due to the adoption by large number of medical practitioners.

Xerostomia Therapeutics Market types

Dentifrices segment is projected to expand at a considerable CAGR

On the basis of products, the market is divided into salivary stimulants, dentifrices, and salivary substitutes. The dentifrices segment is projected to expand at a considerable CAGR during the projected period due to its easy availability, effectiveness, affordability, and higher adoption among end users. Meanwhile, the salivary stimulants segment is anticipated to grow at a substantial rate during the forecast period owing to wide range of products and substitutes along with easy availability.

Xerostomia Therapeutics Market product

North America is anticipated to constitute a key market share

In terms of regions, the global xerostomia therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of the North America is anticipated to constitute a key market share during the targeted years owing to increasing incidences of xerostomia and increasing dry mouth awareness initiatives in the region. The market of Asia Pacific, however, is anticipated to expand at a robust growth rate during the forecast period due to growing healthcare expenditure and various growing initiatives by governments across the region.
 

Segments

Segments Covered in the Report
The global xerostomia therapeutics market has been segmented on the basis of
Types

  • Over the counter
  • Prescription

Products

  • Salivary stimulants
  • Dentifrices
  • Salivary substitutes

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Church & Dwight Co., Inc.
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals Plc
  • Pendopharm, Inc.
  • Sun Pharmaceuticals Industries Ltd.
  • Pfizer, Inc.
  • Parnell Pharmaceuticals, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Colgate-Palmolive Company
  • OraCoat
  • Acacia Pharma Ltd.

 

Competitive Landscape

Key players competing in the global xerostomia therapeutics market are Church & Dwight Co., Inc.; GlaxoSmithKline Plc; Hikma Pharmaceuticals Plc; Pendopharm, Inc; Sun Pharmaceuticals Industries Ltd.; Pfizer, Inc.; Parnell Pharmaceuticals, Inc.; Lupin Pharmaceuticals, Inc.; Colgate-Palmolive Company; OraCoat; and Acacia Pharma Ltd. The main market players are continuously engaged in the activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations. For instance, a major oral care company, Hikma Pharmaceuticals acquired Roxane Laboratories, a part of West-Ward Pharmaceuticals Corp in April 2017 to enhance the product portfolio.

Xerostomia Therapeutics Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Xerostomia Therapeutics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Xerostomia Therapeutics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Xerostomia Therapeutics Market - Supply Chain
  4.5. Global Xerostomia Therapeutics Market Forecast
     4.5.1. Xerostomia Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Xerostomia Therapeutics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Xerostomia Therapeutics Market Absolute $ Opportunity
5. Global Xerostomia Therapeutics Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Xerostomia Therapeutics Market Size and Volume Forecast by Types
     5.3.1. Over the counter
     5.3.2. Prescription
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Xerostomia Therapeutics Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Xerostomia Therapeutics Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Xerostomia Therapeutics Demand Share Forecast, 2019-2026
7. North America Xerostomia Therapeutics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Xerostomia Therapeutics Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Xerostomia Therapeutics Market Size and Volume Forecast by Types
     7.4.1. Over the counter
     7.4.2. Prescription
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Xerostomia Therapeutics Demand Share Forecast, 2019-2026
8. Latin America Xerostomia Therapeutics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Xerostomia Therapeutics Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Xerostomia Therapeutics Market Size and Volume Forecast by Types
     8.4.1. Over the counter
     8.4.2. Prescription
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Xerostomia Therapeutics Demand Share Forecast, 2019-2026
9. Europe Xerostomia Therapeutics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Xerostomia Therapeutics Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Xerostomia Therapeutics Market Size and Volume Forecast by Types
     9.4.1. Over the counter
     9.4.2. Prescription
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Xerostomia Therapeutics Demand Share Forecast, 2019-2026
10. Asia Pacific Xerostomia Therapeutics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Xerostomia Therapeutics Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Xerostomia Therapeutics Market Size and Volume Forecast by Types
     10.4.1. Over the counter
     10.4.2. Prescription
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Xerostomia Therapeutics Demand Share Forecast, 2019-2026
11. Middle East & Africa Xerostomia Therapeutics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Xerostomia Therapeutics Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Xerostomia Therapeutics Market Size and Volume Forecast by Types
     11.4.1. Over the counter
     11.4.2. Prescription
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Xerostomia Therapeutics Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Xerostomia Therapeutics Market: Market Share Analysis
  12.2. Xerostomia Therapeutics Distributors and Customers
  12.3. Xerostomia Therapeutics Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Church & Dwight Co., Inc.
     12.4.2. GlaxoSmithKline Plc
     12.4.3. Hikma Pharmaceuticals Plc
     12.4.4. Pendopharm, Inc.
     12.4.5. Sun Pharmaceuticals Industries Ltd.
     12.4.6. Pfizer, Inc.
     12.4.7. Parnell Pharmaceuticals, Inc.

Buy Report